monoclonal antibodies

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

Biopharmaceutical third-party logistics market expected to surge from $140B (2025) to $384B (2032), driven by complex biologics, regulatory demands, and cold-chain technology innovation.

Over 30 pharma companies develop 35+ severe asthma drugs with recent approvals validating new mechanisms, signaling major market opportunity and competitive intensity ahead.

Spinal cord injury market projected to grow from $354M to $1.4B by 2034 as six emerging therapies target previously untreated condition.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.

Biopharmaceutical CMO market to grow from $21.16B in 2025 to $76.2B by 2035, driven by outsourcing demand and capacity constraints.

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.